RBC Capital analyst Conor McNamara maintained a Buy rating on Danaher (DHR – Research Report) yesterday and set a price target of $260.00. The company’s shares closed yesterday at $226.94. McNamara covers the Healthcare sector, focusing on stocks such as Bio-Rad Laboratories, Illumina, and Repligen. According to TipRanks, McNamara has an average return of -4.1% and a 29.63% success rate on recommended stocks.  Danaher has an analyst consensus of Strong Buy, with a price target consensus of $277.76, representing a 22.39% upside. In a report released on May 7, Jefferies also maintained a Buy rating on the stock with a $310.00 price target. See today’s best-performing stocks on TipRanks >> The company has a one-year high of $302.91  and a one-year low of $226.70. Currently, Danaher has an average volume of 2.86M.
		  Based on the recent corporate insider activity of 60 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DHR in relation to earlier this year. Earlier this month, Walter Lohr, a Director at DHR sold 3,490.00 shares for a total of $840,671.20. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Founded in 1969 and headquartered in Washington, DC, Danaher Corp. engages in manufacturing, designing and marketing of professional, medical, industrial and commercial products and services. The company operates through three segments, including Life Sciences, Diagnostics, and Environmental & Applied Solutions.  Read More on DHR: Indices Commodities Currencies Stocks